EPS for AcelRx Pharmaceuticals Inc (ACRX) Expected At $-0.28

July 26, 2017 - By Nellie Frank

 EPS for AcelRx Pharmaceuticals Inc (ACRX) Expected At $ 0.28
Investors sentiment increased to 2.06 in Q4 2016. Its up 0.84, from 1.22 in 2016Q3. It improved, as 2 investors sold AcelRx Pharmaceuticals Inc shares while 16 reduced holdings. 15 funds opened positions while 22 raised stakes. 14.54 million shares or 6.63% less from 15.57 million shares in 2016Q3 were reported.
Howland Capital Limited invested in 0% or 10,000 shares. Tfs Cap Limited Liability Co has 0.01% invested in AcelRx Pharmaceuticals Inc (NASDAQ:ACRX). Creative Planning invested in 14,600 shares or 0% of the stock. 23,475 are owned by Ny State Common Retirement Fund. Tiaa Cref Management Limited Liability Corp owns 130,335 shares. Osterweis Cap Management holds 0% of its portfolio in AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) for 14,839 shares. Joel Isaacson & Ltd Llc holds 80,660 shares or 0.04% of its portfolio. Barclays Public Ltd Company invested in 0% or 636 shares. 105,740 were reported by Bank & Trust Of Mellon. Guggenheim Cap Limited Liability Company holds 10,580 shares or 0% of its portfolio. Rhumbline Advisers accumulated 31,567 shares. 1.52M are owned by Vanguard Gp. 17,517 are held by Two Sigma Secs Limited Co. Massachusetts-based Granahan Management Inc Ma has invested 0.05% in AcelRx Pharmaceuticals Inc (NASDAQ:ACRX). Salem Counselors reported 3,735 shares.

Investors wait AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) to report on July, 27. its quarterly earnings Wall Street analysts expect $-0.28 EPS, down $0.04 or 16.67 % from last year’s $-0.24 same quarter earnings. AcelRx Pharmaceuticals Inc’s Wall Street analysts see -17.65 % EPS growth, taking into account the $-0.34 EPS reproted in the previous quarter, The stock increased 4.11% or $0.15 during the last trading session, reaching $3.8. About shares traded. AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) has declined 14.24% since July 26, 2016 and is downtrending. It has underperformed by 30.94% the S&P500.

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Ratings Coverage

Among 5 analysts covering AcelRx Pharmaceuticals (NASDAQ:ACRX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AcelRx Pharmaceuticals has $15 highest and $700 lowest target. $9.88’s average target is 160.00% above currents $3.8 stock price. AcelRx Pharmaceuticals had 12 analyst reports since August 4, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, September 2 by H.C. Wainwright. The firm earned “Hold” rating on Tuesday, August 4 by Cowen & Co. The company was maintained on Tuesday, May 3 by H.C. Wainwright. The firm has “Buy” rating given on Friday, October 30 by Jefferies. The firm has “Buy” rating given on Friday, July 14 by Jefferies. TH Capital maintained the stock with “Buy” rating in Monday, October 5 report. The stock has “Buy” rating by Seaport Global on Friday, May 6. The rating was maintained by Roth Capital on Monday, October 5 with “Buy”. The stock of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) earned “Buy” rating by TH Capital on Thursday, September 15.

AcelRx Pharmaceuticals, Inc. is a pharmaceutical firm focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The company has market cap of $199.82 million. The Firm operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. It currently has negative earnings. The Company’s lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03.

More recent AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) news were published by: Seekingalpha.com which released: “AcelRx Pharmaceuticals To Benefit From DSUVIA Launch” on May 31, 2017. Also Seekingalpha.com published the news titled: “AcelRx: Undervalued Heading Into A Phase 3 Catalyst” on July 16, 2017. Prnewswire.com‘s news article titled: “AcelRx Pharmaceuticals Reports First Quarter 2017 Financial Results and …” with publication date: May 08, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.